PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.41%
Negative EBIT growth while TRVN is at 14.24%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-25.41%
Negative operating income growth while TRVN is at 14.24%. Joel Greenblatt would press for urgent turnaround measures.
610.74%
Positive net income growth while TRVN is negative. John Neff might see a big relative performance advantage.
609.26%
Positive EPS growth while TRVN is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
609.26%
Positive diluted EPS growth while TRVN is negative. John Neff might view this as a strong relative advantage in controlling dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
320.27%
OCF growth above 1.5x TRVN's 37.31%. David Dodd would confirm a clear edge in underlying cash generation.
320.27%
FCF growth above 1.5x TRVN's 37.31%. David Dodd would verify if the firm’s strategic investments yield superior returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
419.54%
10Y OCF/share CAGR above 1.5x TRVN's 49.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
419.54%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
400.10%
Positive 3Y OCF/share CAGR while TRVN is negative. John Neff might see a big short-term edge in operational efficiency.
706.07%
Net income/share CAGR above 1.5x TRVN's 60.68% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
706.07%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
315.93%
Positive short-term CAGR while TRVN is negative. John Neff would see a clear advantage in near-term profit trajectory.
-251.89%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-251.89%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-24.04%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
20.74%
Positive BV/share change while TRVN is negative. John Neff sees a clear edge over a competitor losing equity.
-14.44%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
30.71%
SG&A growth well above TRVN's 10.57%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.